We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Juniper Pharmaceuticals, Inc. to Catalent Inc. (NYSE: CTLT) (“Catalent”). Under the terms of the transaction, Juniper shareholders will receive $11.50 for each share of Juniper common stock that they own.
The investigation concerns whether the Board of Juniper Pharmaceuticals, Inc. breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Catalent is underpaying for Juniper shares, thus unlawfully harming Juniper shareholders.
To receive more information, please fill out the form.